Derivation and Long‐Term Culture of Transgene‐Free Human Induced Pluripotent Stem Cells on Synthetic Substrates by Villa-Diaz, Luis Gerardo et al.
Pluripotent Stem Cells
Derivation and Long-Term Culture of Transgene-Free
Human Induced Pluripotent Stem Cells on
Synthetic Substrates
LUIS GERARDO VILLA-DIAZ,a,b JIN KOO KIM,a,b JOERG LAHANN,b,c PAUL H. KREBSBACHa,b
Key Words. Induced pluripotent stem cells x Synthetic coating x Stem cells x
Regenerative medicine x iPSC x Differentiation x Feeder-free culture
ABSTRACT
Wedescribeaplatformtoderive, culture, anddifferentiate genomically stable, transgene-freehuman
induced pluripotent stem cells (iPSCs) on a fully synthetic polymer substrate made of a grafted
zwitterionic hydrogel: poly2-(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl) ammonium hydroxide
(PMEDSAH). Three independent transgene-free iPSC lines derived in these conditions demonstrated
continuous self-renewal, genomic stability, and pluripotency in vitro and in vivo after up to 9months
of continuous in vitro culture on PMEDSAH-grafted plates. Together, these data demonstrate the
strength this alternative platform offers to generate and maintain human iPSCs for regenerative
medicine. STEM CELLS TRANSLATIONAL MEDICINE 2014;3:1410–1417
INTRODUCTION
The indefinite self-renewal and pluripotency ca-
pacity featured by human induced pluripotent
stem cells (iPSCs) makes them a potential source
of cells for regenerativemedicine, drugdiscovery,
disease modeling, and detailed study of self-
renewal and differentiation. Since the first report
demonstrating the derivation of human iPSCs [1],
it was recognized that safety issueswould need to
be resolved for these cells to reach their full po-
tential. The initial focus toward this goal was to
avoid genomic integration of the overexpressed
transgenes (OCT4 [also known as POU5F1],
SOX2, KLF4, and c-MYC) in the resulting iPSC lines
to limit the inherent risk of tumor formation.
Since then, several methods [2–7] have been de-
veloped to generate transgene-free human iPSCs.
To achieve appropriate safety profiles for hu-
man applications, the microenvironment in which
human iPSCs are derived and cultured must also
be considered. Historically, the culture conditions
forhuman iPSCshave followedmethodsdeveloped
for human embryonic stem cells (ESCs), which in
turn were adapted from the culture of mouse ESCs
[8]. Consequently, themajority of human iPSC lines
have been derived and cultured in the presence of
mouse embryonic fibroblasts, human fibroblasts,
orautologouslyderived fibroblasts.However, these
commonly used culture conditions encompass bio-
safety risks such as xenogeneic contamination by
nonhuman sialic acids [9], mycoplasma, and viral
andnonviral infectiousagentsandmaybe immuno-
logically incompatible with human use [10].
Feeder-free systems have been implemented
for culturing human PSCs using extracellular ma-
trix proteins derived from either animal sources
such as Matrigel [11] or synthetically produced
proteins such as human recombinant (hr) laminin
[12], E-cadherin [13], and vitronectin [14]. Re-
cently, the derivation of human iPSCs on hr vitro-
nectin [14] and hr laminins 511 fraction E8 [15]
and 521 [16] was reported, demonstrating the
feasibility of generating xenogeneic-free pluripo-
tent stem cells in feeder-free conditions. Never-
theless, the use of recombinant proteins as a
substrate for the derivation and long-term and
large-scale culture of human iPSCs is not cost-
effective. As an alternative, synthetic coatings
have been developed to support growth of hu-
man ESCs and human iPSCs while maintaining
pluripotency [8]. These synthetic substrates are
superior to biological substrates with respect to
cost effectiveness, stability, consistency, andease
of sterilization. Thus, the use of fully synthetic
substrates for derivation of human iPSCs in
xenogeneic-free and feeder-free conditions could
represent an ideal culture system.
Here, we describe the derivation and long-
term culture of human iPSC lines using a polymer-
based substrate consisting of a grafted zwitterionic
hydrogel: poly2-(methacryloyloxy)ethyl dimethyl-
(3-sulfopropyl) ammoniumhydroxide (PMEDSAH),
which is extremely effective in sustaining the
long-term feeder-free culture of human ESCs [17]
and iPSCs [18]. Three independent human iPSC
lines were derived and continuously cultured for
9 months on this chemically defined substrate.
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PLURIPOTENT STEM CELLS
Rigorous characterization of these cell lines demonstrated a fully
reprogrammedcharacter, in vitro and in vivodifferentiationpoten-
tial, as well as genomic stability.
MATERIALS AND METHODS
Cell Culture
Human gingival fibroblasts (hGF) were derived with approval of
the University of Michigan Institutional Review Board. The deri-
vation procedure followed a protocol detailed previously [19].
The two hGF cell lines labeled as hGF(1) and hGF(2) and human
foreskin fibroblasts (hFFs; American Type Culture Collection,
Manassas, VA, http://www.atcc.org) were cultured in dedicated
incubators in high humidity at 37°C and 5% CO2, with 10% fetal
bovine serum (vol/vol) in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA, http://www.invitrogen.com)
and 13 antibiotic/antimycotic solution (Invitrogen). This culture
medium was changed during the reprogramming cycle and
expansion of human iPSC colonies to human cell conditioned
medium (hCCM; GlobalStem, Gaithersburg, MD, http://www.
globalstem.com) supplemented with 4 ng/ml human recombi-
nant basic fibroblast growth factor (GlobalStem), which is herein
referred to as hCCM+.
PMEDSAH-grafted plates (GPs) were used as a synthetic sub-
strate during the reprogramming cycle and for the long-term
culture of the derived human iPSC lines. The preparation of
PMEDSAH-GPs has been detailed previously [20]. Briefly, the
grafting was performed on tissue culture polystyrene (TCPS)
plates (Becton, Dickinson and Company, Franklin Lakes, NJ,
http://www.bd.com), and polymers were obtained from Sigma-
Aldrich (St. Louis, MO, http://www.sigmaaldrich.com). Graft
polymerization was performed using a 0.2 M solution of methac-
rylatemonomers in a 4:1mixture of water and ethanol. The TCPS
plates were activated using a UV-ozone cleaner (Jelight, Irvine,
CA, http://www.jelight.com) for 40 minutes. Surface-activated
dishes were immersed into monomer solution at 80°C for 2.5
hours. The polymer-grafted dishes were subsequently cooled
to 50°C and rinsed in 1%NaCl-water solution at the same temper-
ature overnight. The grafted plates were cleaned by ultrasonica-
tion in deionized water and dried under a stream of nitrogen gas.
The cell culture on PMEDSAH was performed as previously de-
scribed [20]. Briefly, PMEDSAH plates were prepared as follows:
after overnight UV exposure, plates were washed two times
with phosphate-buffered saline followed by addition of hCCM+.
Then plates were placed and maintained until and during use
in incubators in high humidity at 37°C and 5% CO2. If prepared
PMEDSAH-GPs were not used within a week, hCCM+ was
refreshed. Matrigel-coated plates (CPs) were prepared the day
of intended use following manufacturer’s instructions (BDMatri-
gel hESC-qualified Matrix; BD Biosciences, San Diego, CA, http://
www.bdbiosciences.com). Colonies of human iPSCs (hiPSCs)
were passagedmanually by cutting them into small clusters using
either a pulled-glass pipette or the StemCell Tool (Invitrogen).
Reprogramming Cycle
The reprogramming cycle was performed with minor modifica-
tions to the protocol provided by the CytoTune iPS reprogram-
ming kit (Invitrogen) using Sendai virus (SeV) vectors for human
(h)OCT3/4, hSOX2, hKLF4, and hc-MYC. A schematic timeline of
events is given in supplemental online Figure 1. A cell-doubling
time calculation was performed for all three fibroblast cell lines
to determine the initial cell plating density and to achieve a den-
sity of approximately 3.3 3 105 cells per well of a six-well plate
(Becton, Dickinson and Company) at the time of infection, 48
hours postplating. In total, approximately 1 3 106 cells were
infected with the SV vectors at a multiplicity of infection of 3.
Fromday 1 to day 8, parental fibroblastswere culturedwith fibro-
blast culture medium on six-well plates; at day 8, they were
treated with 0.25% trypsin-EDTA (Gibco, Grand Island, NY, http://
www.invitrogen.com), inactivated with fibroblast medium, and
resuspended in hCCM+. The cell suspension of each parental fi-
broblast line was subdivided into six parts of equal volumes
and distributed into three PMEDSAH-GPs and three Matrigel-
CPs. All plates were 60 mm in diameter and were pre-
equilibrated with hCCM+ supplemented with Rock inhibitor (10
mM; Enzo Life Sciences, Inc., Farmingdale, NY, http://www.
enzolifesciences.com). Thismediumwas replacedevery 48hours,
until day 22 when clonal expansion was performed by selecting
one human iPSC colony per cell line and manually passaged into
a freshly prepared 35-mm PMEDSAH-GPs or Matrigel-CPs. The
resulting subcloned colonies were continuously expanded for 9
months without Rock inhibitor and characterized to assure their
full reprogramming into iPSCs. The expansion of colonies on
Matrigel-CP was terminated at the time of reprogramming effi-
ciency calculation.
Reprogramming Efficiency Calculation
The reprogramming efficiency was calculated for each cell line of
human iPSCs derived on PMEDSAH-GPs and Matrigel-CPs as fol-
lows: the total number of undifferentiated colonies present in the
original PMEDSAH-GPs andMatrigel-CPs plus one at day 30 post-
infection was divided by the corresponding number of parental
fibroblasts found in each substrate at the day of infection. A col-
onywas consideredundifferentiated if it hadwell definedborders
and a high nucleus:cytoplasm ratio and stained positively for al-
kaline phosphatase.
Evaluation of Pluripotency
Pluripotency was tested in vivo by a teratoma formation assay 6
months after derivation and continuous in vitro culture. Briefly,
undifferentiated cells (∼53 106 cells per cell line) from each de-
rived human iPSC line on PMEDSAH-GPs were injected subcuta-
neously into NOD.CB17-PrkcdSCID/NcrCrl mice (Charles River
Laboratories, Wilmington, MA, http://www.criver.com) to in-
duce teratomas. When tumors became palpable after 8–12
weeks, mice were euthanized, and tumors were isolated and pro-
cessed forhistologic analysis. A certifiedpathologist at thePathol-
ogy Core for Animal Research at University of Michigan Medical
School analyzed and identified tissue representative from the
three germ layers in hematoxylin/eosin-stained slides.
For in vitro analysis of pluripotency, embryoid body (EB) for-
mation and directed cell-lineage differentiation from undifferen-
tiated human iPSCs derived and cultured on PMEDSAH-GPs were
performed 3, 6, and 9 months after derivation and continuous in
vitro culture, using established protocols [21]. Undifferentiated
human iPSCs were induced to differentiate in basal medium
consisted of DMEM/F12 (Invitrogen) supplemented with 13 N2
(Invitrogen), 13 B27 (Invitrogen), 2 mM L-glutamine, 0.11 mM
2-mercaptoethanol, 1 mM nonessential amino acids, and 0.5
mg/ml bovine serum albumin (fraction V; Sigma-Aldrich). To
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induce neuronal differentiation, 100 ng/ml human recombinant
Noggin (Stemgent, Cambridge, MA, https://www.stemgent.
com) was added to the basal medium, and cells were cultured
in this condition for 8 days. For definitive endoderm differentia-
tion, 100 ng/ml human recombinant activin A (Stemgent) was
added to basal medium, and cells were cultured for 9 days. The
induction to cardiomyocyte differentiation consisted of two
sequential steps; first, cells were cultured in basal medium plus
50ng/ml human recombinant BMP4 (Stemgent) and50ng/ml hu-
man recombinant activin A for 4 days and then further cultured
in basal medium for an additional 10 days.
Quantitative Real-Time PCR
Total RNAwas extracted using TRIzol (Invitrogen) and purified us-
ing RNeasy Mini Kit (Qiagen) and DNase I treatment. One milli-
gram of total RNA was reverse transcribed into cDNA using
Superscript III Reverse Transcriptase (Invitrogen). Twomicroliters
of diluted reverse transcribed cDNA (reverse transcription [RT] re-
action, 1:5 in RNase-free water) were amplified in a polymerase
chain reaction (PCR) assay (30ml) using TaqManGene Expression
Master Mix (Applied Biosystems, Foster City, CA, http://www.
appliedbiosystems.com), target primers, and probes (unlabeled
PCRprimers and a carboxyfluorescein dye-labeled TaqManminor
groove binderprobe) (Applied Biosystems). Gene expression was
determined by quantitative real-time PCR on an ABI Prism 7700
Sequence Detection System (Applied Biosystems). The relative
RNA expression levels of target genes were analyzed by the
comparative DDCT method using b-actin as an internal control.
Subsequently, expression levels of investigated genes were
normalized to expression levels of control samples and reported
as fold changes.
RT-PCR Analysis
Total RNA was reverse transcribed using SuperScript One-Step
RT-PCR with platinum Taq (Invitrogen). In a single reaction (25
ml), 0.5 mg of total RNA, and 20 pmol of forward and reverse pri-
mers were used (supplemental online Table 3). The cDNA synthe-
sis and predenaturation were carried out at 95°C for 2 minutes.
The PCR amplification was performed for 35 cycles at 95°C for
30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds. The fi-
nal extension cycle was run at 72°C for 10 minutes. Finally, 10 ml
of PCR product was loaded onto a 1.0% agarose gel and size-
fractionated.
Chromosomal Stability Studies Using High-Resolution
aCGH and G-Banding Karyotype
The array-based comparative genomic hybridization (aCGH)
135K Stem Array (Ambry Genetics, Aliso Viejo, CA, http://www.
ambrygen.com) was performed by Cell Line Genetics (Madison,
WI, http://www.clgenetics.com) on cells continuously passaged
for 9 months as follows: genomic DNA quality and concentration
were determined with a NanoView spectrophotometer. Labeling
reactions were prepared using the NimbleGen labeling protocol
for aCGH (version 8.0; Roche, Indianapolis, IN, http://www.
roche.com) with 500–600 ng of total (RNased) DNA input. The
StemArray protocol consists of labeling of the DNA and hybridiza-
tion. First, 500–600 ng of test sampleDNAwas labeledwith cyanine
3-dUTP, and pooled sex-matched reference DNA was labeled with
cyanine 5-dUTP by Exo-Klenow fragment. Labeled DNA was puri-
fied, and the labeling efficiency/concentration was determined
by the NanoView spectrophotometer. Test and reference sam-
ples were balanced by combining 20 mg of labeled test sample
and20mgof corresponding labeled reference sample intoa single
reaction tube. The labeled DNA was prepared for hybridization
and placed on the 135K StemArray and hybridized at 42°C for
∼72 hours. Arrays were then washed and scanned at 2 mM re-
solution on a NimbleGen MS 200 High Resolution Scanner.
Data were extracted using Nimblescan version 2.6 image ex-
traction software, processed, andmapped to the human genome
(hg19) using FASST2 Segmentation Algorithm in Nexus Copy
Number version 6.0 (Biodiscovery, Hawthorne, CA, http://
www.biodiscovery.com). The aberration detection settingswere:
minimum probe, 5; significance threshold, 1.03 10E-7; high gain,
1.0; gain, 0.3; loss,20.3; big loss,21.1. For standard G-banding
karyotyping, chromosomes from at least 20 cells at the meta-
phase stage were prepared using standard protocols and ana-
lyzed by Cell Line Genetics.
Western Blot Analysis
The following antibodieswere used: antibody to Sendai virus pro-
tein (1:1,000; MBL International Corp., Woburn, MA, http://
www.mblintl.com), Oct4-specific antibody (1:2,000; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, http://www.scbt.com),
Nanog-specific antibody (1:1,000; Cell Signaling Technology,
Beverly,MA, http://www.cellsignal.com),a-tubulin-specific anti-
body (1:2,000; Santa Cruz Biotechnology Inc.), and b-actin-
specific antibody (1:1,000; Cell Signaling Technology). Whole cell
lysates were prepared from cells, separated on 7.5% SDS-
polyacrylamide gel, and transferred to polyvinylidene difluoride
membranes. The membranes were incubated with 5% milk in
TBST (wt/vol) for 1 hour and then incubated with primary anti-
bodies overnight at 4°C. Blots were incubated with peroxidase-
coupled secondary antibodies (Promega, Madison, WI, http://
www.promega.com) for 1 hour, and protein expression was
detectedwith SuperSignalWest PicoChemiluminescent Substrate
(ThermoScientific,Waltham,MA,http://www.thermoscientific.com).
Immunocytochemistry
Cells were fixed in 2% paraformaldehyde (wt/vol) for 30 minutes
at room temperature and, if required, permeabilized with 0.1%
Triton X-100 (vol/vol) for 10minutes. Primary antibodies were di-
luted in1%normal serum (vol/vol) and incubatedovernight at 4°C
and detected by respective secondary antibodies. Samples were
imaged and captured using a Leica DM IRB inverted microscope
(Leica, Heerbrugg, Switzerland, http://www.leica.com) with an
Olympus (Center Valley, PA, http://www.olympusamerica.com)
DP-30 CCD camera (Microscopy and Image Analysis Laboratory,
University of Michigan, Ann Arbor, MI). The following antibodies
wereused:GATA4-specific antibody (R&DSystems Inc.,Minneap-
olis, MN, http://www.rndsystems.com), HNF-3b/FoxA2-specific
antibody (R&D Systems, Inc.), SOX1-specific antibody (R&D Sys-
tems, Inc.), PAX6-specific antibody (Abcam, Cambridge, U.K.,
http://www.abcam.com), SSEA-3-specific antibody (Millipore,
Billerica,MA, http://www.millipore.com), TRA-1-60-specific anti-
body (Santa Cruz Biotechnology Inc.), TRA-1-81-specific antibody
(Millipore), SSEA4-specific antibody (Santa Cruz Biotechnology
Inc.), Oct3/4-specific antibody (Santa Cruz Biotechnology Inc.),
Nanog-specific antibody (Cell Signaling Technology), and Sox2-
specific antibody (Millipore).
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Bisulfite Sequencing
Genomic DNA (1 mg) was treated with components of the CpGe-
nome DNA modification kit (Chemicon, Temecula, CA, http://
www.chemicon.com), according to the manufacturer’s recom-
mendations. Treated DNA was purified with QIAquick column
(Qiagen, Hilden, Germany, http://www.qiagen.com). The pro-
moter regions of human OCT4 and NANOG genes were amplified
by PCR. The PCRproductswere subcloned into pCR2.1-TOPO. Ten
clones of each sample were verified by sequencing with the M13
universal primer. Primer sequences [22, 23] used for PCR ampli-
fication are shown in supplemental online Table 3.
Statistical Analysis
Experiments were performed in triplicate, and the data are
expressed as mean values 6 SD and analyzed by an unpaired t
test. Levels of statistical significance were set at p, .05.
RESULTS
Derivation of Human Induced Pluripotent Stem Cells
on PMEDSAH-GP
The parental cell lines, two derived from adult gingival tissue
(hGF) and a commercial cell line from newborn foreskin (hFF),
were initially cultured and infected with the reprogramming fac-
tors introduced by SeV on tissue culture plastic plates, and 5 days
postinfectionwere subcultured, equally divided, and reseededon
PMEDSAH-GPs and Matrigel-CPs (used as control) in hCCM+
(supplemental online Fig. 1). During this period and until the first
passage of colonies, themediumwas supplementedwith Rock in-
hibitor. Nine days postinfection, colonies were observed on both
PMEDSAH-GPs and Matrigel-CPs. At day 16 postinfection, two
colonies growing on PMEDSAH-GPs were subcloned to evaluate
the expression of Nanog and alkaline phosphatase activity
(supplemental online Fig. 1). At day 22 postinfection, one colony
from each of the three parental lines growing on both PMEDSAH-
GPs and Matrigel-CPs was selected, manually dissected, and
reseeded on new substrates. Subsequently, six human iPSC lines
were established, two from each parental cell line, from which
onewas derived and propagated on PMEDSAH-GPs and the other
on Matrigel-CPs. At day 30 postinfection, the reprogramming ef-
ficiency was calculated and ranged from 0.0004% to 0.0006%.
There was no statistical difference (p . .05) between parental
fibroblasts and substrates. The number of colonies generated
in each condition (178 6 75 [average 6 SD]) exceeded the re-
quired number to establish and characterize independent human
iPSC lines. This suggests that PMEDSAH-GP is an effective plat-
form to generate human iPSCs.
Characterization of Human iPSCs Derived on
PMEDSAH-GPs
The three human iPSC lines derived on PMEDSAH-GPs were sub-
cultured on grafted plates of the same synthetic substrate for ap-
proximately 170 cell doublings over a period of 9 months and
continuously characterized to demonstrate their fully reprog-
rammed character. Initially, Western blot analysis demonstrated
that parental fibroblasts did not express Oct4. In contrast, Oct4
was highly expressed in cells undergoing reprogramming and in
fully established human iPSCs, 3 months after derivation and cul-
ture (Fig. 1A). SeV protein levels were not detected in parental
fibroblasts but were high 3 days postinfection and subsequently
decreased to undetectable levels in human iPSCs (Fig. 1A). RNA
expression of SeV was also tested by RT-PCR, showing no detect-
able levels in established human iPSC lines (supplemental online
Fig. 2). The expression of Nanog in all iPSC lines was detected
by Western blot analysis (Fig. 1B), and immunocytochemistry
revealed the continuous expression of pluripotent markers:
Oct4, SSEA3, SSEA4, TRA-1-60, TRA-1-81, and Sox2 (Fig. 1C). Bisul-
fite sequencing analysis demonstrated that promoters of OCT4
andNANOGwerehighlymethylated in parental cell lines and con-
verted to a largely unmethylated state in established human
iPSCs, 3months after derivation and continuous culture (Fig. 1D).
The pluripotency of the human iPSC lines derived and cul-
tured on PMEDSAH-GPs was tested up to 9 months after deriva-
tion and continuous in vitro culture, by EB formation, in vitro cell
lineage differentiation, and teratoma formation. In vitro, clusters
of iPSC lines formedEBswhen cultured in suspension (Fig. 2A) and
expressed genes representative of the three germ layers: ecto-
derm, endoderm, andmesoderm (data not shown). Furthermore,
specific cell lineage differentiation on PMEDSAH-GPs was di-
rected via chemically defined conditions using well-established
protocols [21]. For neural differentiation, treatment with Noggin
resulted in upregulation of Pax6 RNA levels (Fig. 2B) and dual ex-
pression of Pax6 and Sox1 in treated cells (Fig. 2C). Activin A treat-
ment induced the differentiation of human iPSCs into definitive
endoderm/pancreatic cells, as indicated by high RNA levels of
SOX17 and FOXA2 (Fig. 2B), and detection of FoxA2+ cells (Fig.
2D). Cardiac muscle lineage differentiation in response to Activin
A and BMP4 treatment represented in vitro mesodermal lineage
development, which was confirmed by the upregulation of T,
TNNI3, NKX2.5, and HESX1 (Fig. 2B) and by expression of Gata4
(Fig. 2E). Teratoma analysis confirmed the pluripotency of these
cell lines in vivo, as observed by identification ofmature cells such
as neurons, cartilage, gut glandular epithelium, and other differ-
entiated tissues (Fig. 2F–2H).
Genomic Stability of Human iPSCs Derived and Cultured
on PMEDSAH-GPs
The genetic stability of human iPSCs derived on PMEDSAH-GPs
was analyzed 9 months after derivation and continuous in vitro
culture. Standard G-band analysis demonstrated normal male
chromosomal karyotypes for all three human iPSC lines (Fig. 3A),
whereas aCGH analysis detected minimal gains and losses in spe-
cific chromosomal regions in all cell lines (Fig. 3B; supplemental
online Table 1). It was observed that some of the aberrations were
recurrent in two of the three human iPSC lines and only in one oc-
casion (chromosome 9q34.3) in all cell lines (supplemental online
Table 2).
DISCUSSION
Three independent human iPSC lines derived in xenogeneic and
integration-free conditions demonstrated continuous self-renewal,
genomic stability, and pluripotency in vitro and in vivo after up to
9 months of continuous in vitro culture on PMEDSAH-GPs. These
results demonstrate that PMEDSAH-GPs support the derivation
and long-term self-renewal of genomically stable human iPSCs, as
well as differentiation of into derivatives of the three germ lineages
in chemically defined conditions. The fully reprogrammed character
of the cell lines was demonstrated by continuous expression of
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protein markers related to human pluripotent stem cells, the deme-
thylated status of bothNanogandOct4promoters in these cells, and
the capability to differentiate both in vivo and in vitro into represen-
tative cells and tissues of all three germ layers.
The human iPSC lines derived in these conditions were
transgene-free because nonintegrating Sendai virus constructs
encoding OCT4, SOX2, KLF4, and c-MYC were used to induce
the reprogramming. The Sendai viruses are nonsegmented
Figure1. Expressionofpluripotent-relatedmarkers andmethylation statusofhuman iPSCsderivedonpoly2-(methacryloyloxy)ethyl dimethyl-
(3-sulfopropyl) ammoniumhydroxide (PMEDSAH)-graftedplates (GPs). (A):Westernblot analysis demonstrating theexpressionof SeVandOct4
in the three independent human iPSC lines derived and cultured for 3months on PMEDSAH-GPs and comparedwith parental fibroblasts before
and3days after infection.b-Actinwas used as loading control. (B):Western blot confirming theexpression ofNanog in the three established cell
lines 3months after derivation and continuous in vitro culture.a-Tubulinwas used as loading control. (C):Representative epifluorescentmicro-
graphs of human iPSC colonies 9 months after derivation and continuous in vitro culture, showing expression of Oct4, SSEA3, SSEA4, TRA-1-60,
TRA-1-81, andSox2. Scalebars =100mm. (D):Representative comparative bisulfite genomic sequencing analysis ofOCT4andNANOGpromoters
in parental cells and human iPSCs 3months after derivation and continuous in vitro culture. Open and closed circles indicate unmethylated and
methylated CpGs, respectively. Abbreviations: d, day(s); hFF, human foreskin fibroblast; hGF, human gingival fibroblast; hiPSC, human induced
pluripotent stem cell; iPSC, induced pluripotent stem cell; SeV, Sendai virus.
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negative-strand RNA viruses that do not have a DNA phase and
thus do not integrate into the genomeof infected cells [24]. In ad-
dition, Sendai virus constructs were also selected to induce
reprogramming because of their highly effective infection rates
and simplicity of use compared with other methods that require
multiple transfections to achieve strong gene expression, contin-
uous protein translation, or further manipulations to excise
integrated constructs. Indeed, our data demonstrated the
effectiveness of these vectors to induce reprogramming on
PMEDSAH-GPs. Our results demonstrate that in fully repro-
grammed cells, RNA expression and protein levels of Sendai virus
become undetectable after the establishment of fully repro-
grammed cells (Fig. 1; supplemental online Fig. 2). We have also
derived human iPSCs using Cre/LoxP constructs on PMEDSAH-
GPs (data not shown), which suggests that other nonintegrating
methods could be used in combination with this synthetic sub-
strate to derive transgene-free human iPSC lines.
It has been established that during long-term culture of plu-
ripotent stem cells, chromosomal changes may occur, and these
aberrations may confer growth advantages and disrupt differen-
tiation capacity [25]. In addition, it has been reported that SOX2,
c-MYC, and KLF4may be duplicated in retrovirus-generated iPSCs
because of genomic integration [26]. Therefore,we evaluated the
genomic stability of the three human iPSC lines derived and prop-
agated continuously on PMEDSAH-GPs after 9 months (Fig. 3).
The standard G-banding assay demonstrated a normal karyotype
Figure 2. Evaluation of pluripotency of human induced pluripotent stem cells (iPSCs) derived and cultured on poly2-(methacryloyloxy)ethyl
dimethyl-(3-sulfopropyl) ammonium hydroxide (PMEDSAH)-grafted plates (GPs). The pluripotency of the three human iPSCs derived and cul-
tured on PMEDSAH was tested by embryoid body (EB) formation, directed in vitro cell lineage differentiation, and teratoma induction. (A):
Representative micrograph of EBs from human foreskin fibroblast induced pluripotent stem cells 9 months after derivation and continuous
in vitro culture. (B): Graph showing relative RNA transcription levels of genes expressed in cells after directed in vitro differentiation of human
iPSCs on PMEDSAH-GPs. (C–E): Representative micrographs of directed in vitro cell lineage differentiation on PMEDSAH-GPs of human iPSCs 9
months after derivation and continuous in vitro culture. Neural differentiation (ectoderm) was achieved after treatment with Noggin (B, C).
Definitive endoderm/pancreatic differentiation was induced by activin A treatment (B, D). Mesoderm lineage was obtained after treatment
with activin A and BMP4 to induce cardiac muscle differentiation (B, E). Teratoma formation was performed 6 months after derivation and
continuous in vitro culture of human iPSCs. (F–H): Representative micrographs of neurons (F), gut glandular epithelium (G), and cartilage
(H) identified in teratomas. Scale bars = 200 mm (A), 100 mm (C–E), and 50 mm (F–H). Abbreviation: DAPI, 49,6-diamidino-2-phenylindole.
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for all three cell lines, confirming previous results with hESC cul-
ture on PMEDSAH-GPs [17]. The aCGH analysis demonstrated
minimum modifications in the three cell lines. However, these
mutations do not match chromosomal loci where key stem cell
and cancer-related genes are contained [26] or where genes re-
lated to culture adaption, such as BCL2L1, are localized [27]. Be-
cause the aCGH analysis was performed only in parental cells and
after 9 months of continuous culture of the derived human iPSC
lines, we could not determine the time at which these mutations
occurred, or whether other mutations were corrected [27]. Thus,
these results indicate the genomic stability of human iPSCs de-
rived and cultured long term on PMEDSAH-GPs.
During the preparation of this work, it was reported that
a new chemically defined and xeno-free medium supports the
derivation of human iPSCs on vitronectin [14].When thismedium
was used in combination with PMEDSAH-GPs, only pre-iPSC col-
onies were formed, and cells were not induced to be fully repro-
grammed (data not shown). This observation indicates that further
optimization of chemically defined media is required to achieve
a complete chemically defined and xeno-free platform for the
derivation and culture of human iPSCs on PMEDSAH-GPs, and
work is in progress to achieve this goal.
CONCLUSION
This study demonstrated a feeder-free platform to derive, ex-
pand, and differentiate genomically stable and transgene-free
human iPSCs. This platform has the potential to be in compliance
with good tissue practice and goodmanufacturing practice. Com-
pared with currently used methods, the conditions presented
here represent an alternative to the goal of generation and
long-term propagation of human iPSCs with potential for clinical
application.
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